Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055

MERCK & CO., INC. (MRK)

115
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

06/13/2012 | 08:52am US/Eastern
Recommend:
0
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

Recommend :
0
React to this article
Latest news on MERCK & CO., INC.
1d ago MERCK : Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for ..
2d ago MERCK : New Cytokines Data Have Been Reported by Researchers at Merck & Company ..
2d ago MERCK : Data on Biopharmaceuticals Reported by Researchers at Merck & Company (I..
2d ago MERCK : Announces Fourth-Quarter 2014 Dividend
3d ago EXCLUSIVE - INDIA'S LUPIN, U.S. FIRM : sources
3d ago India's Lupin, U.S. firms weigh bids for GSK's mature drugs -sources
3d ago RECKITT BENCKISER : Aurelius buying Scholl shoes
4d ago Aurelius buys Scholl shoe business from Reckitt Benckiser
07/16 MERCK : Study Results from Merck & Company Broaden Understanding of Herpes Zoste..
07/16 MERCK : New Findings from Merck & Company in the Area of Immunoglobulins Describ..
Advertisement
Chart
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
Merck _ Co., Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF